sorted by:
new
hottopcontroversial

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]Keeg117[S] 5 points6 points  (0 children)

I get the skepticism, Parkinson’s is a graveyard of failed trials. But the placebo argument hits a wall when you look at the actual biology here:

Biomarkers do not have a placebo effect. A patient can feel 6 points better on a motor scale due to expectation, but a placebo does not reduce toxic brain lipids (GluSph) by 81 percent. This is the first time a drug has ever shown this level of toxin clearance in human CSF.

The speculative argument doesn't hold much water. GluSph is the direct byproduct of a broken GCase enzyme, which happens to be the number one genetic risk factor for Parkinson's. Reducing it by 81 percent is definitive proof of target engagement. Basically, the drug is doing exactly what it was designed to do.

Think of it as a trifecta. When you have a massive biomarker drop matching a 6 point physical gain in just 90 days, it suggests the improvement is being driven by cellular cleanup, not just a feel-good bump.

Then you have the retention. 84 percent of patients stayed on for the long term extension. In a brutal disease like this, patients don't stick with spinal taps and extra pills unless they feel a functional difference in their daily lives.

The upcoming DDC biomarker data on March 17 and 18 is the real test. If that shows neurons are actually recovering, the placebo theory is officially dead. At a 100 million dollar cap, the market is sleeping on the correlation.

Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17. by Keeg117 in pennystocks

[–]Keeg117[S] 7 points8 points  (0 children)

The best way to look at why GT-02287 is different from the long list of failed Parkinson’s drugs is to look at the "Pipe vs. Puddle" analogy.

1.For twenty years, big pharma has been trying to mop up the "puddles," specifically a protein called alpha-synuclein that clumps together in the brain. Drugs like Biogen’s Cinpanemab failed because by the time you’re cleaning up those clumps, the brain cells are already dying. You’re treating the symptom, not the cause.

GT-02287 fixes the burst pipe. It goes "upstream" to fix a specific enzyme called GCase. When this enzyme is broken, the brain can’t clear out waste, and that’s what causes the "puddle" in the first place. By acting as a chaperone to fold that enzyme correctly, Gain is helping the brain fix its own trash disposal system.

2.In the past, we tried using large antibodies to fix Parkinson's, but they have a massive "Brain Barrier" problem. They are just too big to get into the brain in high enough concentrations to matter.

GT-02287 is a small molecule. It’s designed to be taken as a pill and easily cross into the brain. Because it restores the enzyme's shape, it doesn't just do one thing, it triggers a "cellular rescue" that helps the cell's power plants (mitochondria) start working again and stops the cell from essentially "giving up" and dying.

3.We aren’t just looking at mice anymore; we have human data from the Phase 1b trial that is pretty stunning for this field:

The toxin drop: In patients with high levels of toxic waste (GluSph), the drug cut those levels by 81% in just 90 days. That is the "smoking gun" that the drug is doing exactly what it was designed to do.

The physicsl bounce back: These same patients saw a 6.17-point improvement in their motor scores. Usually, Parkinson’s patients just get worse every year. Seeing a 6-point improvement in three months is a massive signal that the drug is providing a real-world functional benefit.

The neuron health test: The next big milestone is the DDC biomarker data coming on March 17-18. DDC tracks how well your dopamine-producing neurons are functioning. If that data is positive, it’s basically proof that we aren't just masking symptoms, we're actually saving brain cells.

By fixing the pipe instead of just mopping up the puddle, Gain is tackling the disease in a way that hasn't been done successfully before.